YOU ARE NOW CONNECTED TO THE TOXLINE (1981 FORWARD, NON-ROYALTY) FILE. ==KELOIDS AND HYPERTROPHIC SCARRING== 2 AUTHOR Janssen de Limpens AMP TITLE Local treatment of hypertrophic scars and keloids with topical retinoic acid SOURCE Br. J. Dermatol.; VOL 103 ISS Sep 1980, P319-323, (REF 20) ABSTRACT IPA COPYRIGHT: ASHP In a clinical trial, 28 intractable cases with scars were treated with daily applications of a 0.05% solution of retinoic acid (tretinoin). The results were evaluated objectively and subjectively. Slight to moderate reduction of the size of these scars and decrease of such complaints as itching were noted in the majority of the cases. A favorable result was obtained according to the patients in 79%, and according to the opinion of the medical examiner in 77% of the patients. 3 AUTHOR Dolynchuk KN AUTHOR Ziesmann M AUTHOR Serletti JM TITLE Topical putrescine (Fibrostat) in treatment of hypertrophic scars: phase II study. SOURCE Plast Reconstr Surg; VOL 97, ISS 1, 1996, P117-23; discussion 124-5 ABSTRACT Previous studies indicated that tissue transglutaminase plays a role in the cross-linking of type III procollagen in wound matrices and that this may be inhibited by 50 mM putrescine in vitro. For this reason, the clinical effect of 50 mM putrescine in a eutectic vehicle (Fibrostat) was studied in this phase II double-blind crossover study in 43 patients. Twenty of the patients had had recent surgery and were studied for product safety rather than efficacy. No toxic effects were observed in this group of patients, and only 1 of the 23 unoperated patients had a rash during treatment. The observed effect of Fibrostat versus sham treatment of 1 month's duration in active hypertrophic scar was a significant improvement of hypertrophy in 23 patients during the Fibrostat treatment arm, regardless of the order in which treatment was received. It is suggested that Fibrostat is a safe therapeutic agent for treatment of hypertrophic scar. Clinical examples to illustrate its use are given. 4 AUTHOR Fulton JE Jr TITLE Silicone gel sheeting for the prevention and management of evolving hypertrophic and keloid scars. SOURCE Dermatol Surg; VOL 21, ISS 11, 1995, P947-51 ABSTRACT BACKGROUND. Hypertrophic scars and keloids remain a problem for surgeons. Topical and intralesional corticosteroids, positive pressure dressings, cryotherapy, and laser therapy are helpful but not uniformly successful. OBJECTIVE. To document the effectiveness of silicone gel sheeting in the prevention and/or reduction of evolving hypertrophic scars and keloids. METHODS. Silicone gel sheeting was placed over evolving scars in 20 cases. The dressing was worn for at least 12 hours a day. Biopsies were examined for the presence of silica in the tissue. RESULTS. Lesions improved during the treatment period in 85% of the cases. The mechanisms of action are unknown. Positive pressure was not necessary. No silica from the dressing was found at the wound site. CONCLUSION. Daily treatments with silicone gel sheeting should begin as soon as an itchy red streak develops in a maturing wound. The dressing is effective in reducing the bulk of these lesions. 5 AUTHOR Katz BE TITLE Silicone gel sheeting in scar therapy. SOURCE Cutis; VOL 56, ISS 1, 1995, P65-7 ABSTRACT The purpose of this study was to analyze the efficacy of silicone gel sheeting in the treatment of fresh and long-standing hypertrophic and keloid scars. All subjects applied the gel sheeting in the same fashion and wore it for twelve to twenty-four hours per day for at least two months. After at least six months' follow-up, twenty of thirty-six (56 percent) chronic scars were improved. Eleven of fourteen fresh hypertrophic scars (79 percent) did not recur after surgery during a similar follow-up period. Side effects were minimal. Silicone gel sheeting is safe and effective treatment for hypertrophic and keloid scars. The mechanism of action is not completely understood. 7 AUTHOR Larrabee WF Jr AUTHOR East CA AUTHOR Jaffe HS AUTHOR Stephenson C AUTHOR Peterson KE TITLE Intralesional interferon gamma treatment for keloids and hypertrophic scars. SOURCE Arch Otolaryngol Head Neck Surg; VOL 116, ISS 10, 1990, P1159-62 ABSTRACT Keloids and hypertrophic scars are characterized by excessive collagen formation. Interferon gamma is a lymphokine that can down-regulate collagen synthesis in vitro and in vivo and, therefore, has potential therapeutic benefit in the management of abnormal scars. Intralesional scar injections of interferon gamma were performed to determine the tolerance toxicity and to obtain preliminary evidence for the efficacy of this treatment in the management of hypertropic and keloid lesions. All scars decreased in linear dimensions and flattened out. Five of 10 scars studied decreased at least 50% in linear dimensions. Interferon gamma can safely be administered intralesionally once per week up to a dosage of 0.05 mg for 10 weeks with no serious toxic effects. The commonest reported side effect was a mild headache.